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Skin and soft tissue infections (SSTIs) are a major therapeutic challenge for clinicians. The
emergence of pathogens with decreased susceptibility to available therapies has become
an emerging problem often associated with treatment failure. Hence, there is an urgent
need for novel broad-spectrum antimicrobial agents. The purpose of this study was to
assess the feasibility of chlorquinaldol as an alternative approach to currently used topical
antibiotics for the treatment of skin and soft tissue infections. The activity of chlorquinaldol
was investigated against a collection of bacterial isolates responsible for skin infections,
including strains resistant to fusidic acid and gentamicin. After determination of MIC
and MBC, time-kill experiments were carried out by counting colonies grown after 0,
3, 6, 9, 24, and 48 h of incubation with concentrations equal to ¼×, ½×, 1×, 2×,
and 4× MIC of chlorquinaldol, gentamicin, or fusidic acid. Staphylococci resulted the
Gram-positives most sensitive to chlorquinaldol, with MIC-values ranging from 0.016 to
0.5 mg/L. A lower activity was observed against Gram-negative bacteria, with 77% of
the isolates being inhibited at concentrations ranging from 128 to 512 mg/L. Generally, in
time-kill studies, chlorquinaldol showed a bactericidal activity at the higher concentrations
(2×, 4× MIC) after 24–48 h of incubation. In conclusion, chlorquinaldol may represent a
valuable alternative to conventional topical antibiotics for the treatment of skin and soft
tissue infections.
Keywords: chlorquinaldol, gentamicin, fusidic acid, skin infections, time-kill curves, minimum inhibitory
concentration, minimum bactericidal concentration
INTRODUCTION
Skin and soft tissue infections (SSTIs) are commonly occurring diseases with a wide-range of
clinical manifestations varying from minor superficial to life-threatening infections (Ray et al.,
2013). Theymay range from “simple uncomplicated” infections, such as erysipelas, cellulitis, simple
abscesses, furuncles, and wound infections, to deeper “complicated” infections, such as necrotizing
fasciitis, myositis, and gas gangrene.
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The etiology of SSTIs is dominated by Staphylococcus aureus,
but other common isolates include β-haemolytic streptococci,
enterococci, Enterobacteriaceae, anaerobes, and Pseudomonas
aeruginosa (Lipsky et al., 2007).
SSTIs are caused by microorganisms multiplication, leading
to prolonged inflammatory response, delays in collagen synthesis
and epithelialization, and tissue damage. Even though careful
attention is paid to patients with acute infections, treatment often
fails in chronic ones, where healing is hampered by the presence
of bacterial biofilm (Bjarnsholt, 2013).
Despite high rate of morbidity and significant burden to the
health care system, the management of skin lesions is still far
from being completely effective and novel therapies are urgently
needed (van Koppen and Hartmann, 2015).
Topical antibiotics are key components in the management of
skin lesions. However, cases of sensitization are not uncommon
(Bonamonte et al., 2014). Poor penetration and variable
antimicrobial concentration can lead to resistance and scarce
efficacy (Esposito et al., 2016). The emergence of pathogens
with decreased susceptibility to available antibiotics has become
an emerging clinical problem often associated with treatment
failure, even with topical drugs of choice, such as fusidic acid
(Heng et al., 2013). Fusidic acid monotherapy, in particular as
topical preparation, is frequently used in dermatology and has
been linked to the emergence of fusidic acid resistance in MSSA
and MRSA (Heng et al., 2013).
Hence, there is an urgent need for novel broad-spectrum
antimicrobial agents, which can be used to successfully treat
cutaneous infections and overcome antibiotic resistance.
Chlorquinaldol, or hydroxydichloroquinaldine (5,7-dichloro-
2-methyl-8-quinolinol), is a derivative of 8-hydroxyquinoline
which is usually administered topically for the treatment of skin
infections, alone or in combination with diflucortolone valerate
(Maeder et al., 1983; Hoppe, 1988; Corrihons et al., 1991). In
few past studies, chlorquinaldol has proven to be effective in
vitro against a wide variety of fungi and a few bacterial species,
and in vivo against a series of cutaneous conditions involving
microbial infections or allergic skin conditions for which
a supplementary anti-infective treatment, for prophylaxis or
therapy, was indicated (Littman, 1955; Robinson and Hollander,
1956; Mann et al., 1960; Regös et al., 1979; Meyer-Rohn and
Puschmann, 1980; Maeder et al., 1983; Kolev et al., 1987; Hoppe,
TABLE 1 | MIC and MBC ranges for Gram-positive bacterial strains.
Chlorquinaldol Gentamicin Fusidic acid
MIC (mg/L) MBC (mg/L) MIC (mg/L) MBC (mg/L) MIC (mg/L) MBC (mg/L)
MRSA 0.125–0.25 0.125–4 2–>512 2–>512 0.016–0.032 0.125–2
MSSA 0.25–0.5 1–4 2–>512 2–>512 0.016–2 0.125–2
MRSE 0.016–0.5 0.032–4 0.25–512 0.25–128 <0.016–8 <0.016–64
E. faecalis 0.25–2 0.25–2 NT NT 4–16 16–512
S. pyogenes 8–32 32–128 NT NT 4–8 16–64
P. acnes 16–32 32–512 >512 >512 0.125–0.5 2–16
NT, not tested because of intrinsic resistance to gentamicin.
1988; Corrihons et al., 1991; Sikorski et al., 1992; Zlatkov
et al., 1996). Despite these promising observations, no further
studies about the antimicrobial activity of chlorquinaldol were
performed and recent investigations are lacking.
The purpose of this study was to assess the feasibility
of chlorquinaldol as a potential alternative approach
to currently used topically applied antibiotics for the




Clinically relevant strains isolated from SSTIs at the
Laboratory of IRCCS Galeazzi Orthopedic Institute were
used. In particular, methicillin-resistant S. aureus (MRSA,
n = 9), methicillin-susceptible S. aureus (MSSA, n = 8),
methicillin-resistant Staphylococcus epidermidis (MRSE, n
= 13), Streptococcus pyogenes (n = 6), Enterococcus faecalis (n =
13), Propionibacterium acnes (n= 10), Proteus mirabilis (n= 11),
P. aeruginosa (n= 12), Escherichia coli (n= 12), and Enterobacter
spp. (n= 12) were used. Identification of the isolates was carried
out on a Vitek2 Compact (BioMerieux, Marcy L’Etoile, France)
and further confirmed by pyrosequencing (PSQ96RA, Diatech,
Jesi, Italy).
TABLE 2 | MIC and MBC ranges for Gram-negative bacterial strains.
Chlorquinaldol Gentamicin
MIC (mg/L) MBC (mg/L) MIC (mg/L) MBC (mg/L)
GENTAMICIN-SUSCEPTIBLE STRAINS (MIC ≤ 4 mg/L)
E. coli 8–128 >512 2–4 4–8
Enterobacter spp. 128–512 >512 2–4 2–8
P. mirabilis 512 >512 4 4
P. aeruginosa 128–512 512–>512 2–4 4–32
GENTAMICIN-RESISTANT STRAINS (MIC > 4 mg/L)
E. coli 8–512 >512 8–>512 8–>512
Enterobacter spp. 128–512 >512 64–>512 64–>512
P. mirabilis 32–512 256–>512 8–>512 16–>512
P. aeruginosa 32–256 128–>512 128–>512 256–>512
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TABLE 3 | MIC distributions (mg/L).




MRSE 1 1 1 4 4 2
E. faecalis 1 2 9 1
S. pyogenes 3 2 1
P. acnes 4 6
E. coli 9 1 1 1
Enterobacter spp. 3 6 3
P. mirabilis 1 5 5
P. aeruginosa 2 5 4 1
GENTAMICIN
MRSA 5 1 1 2
MSSA 3 4 1
MRSE 4 1 1 3 3 1
P. acnes 10
E. coli 1 5 1 1 1 2 1
Enterobacter spp. 4 4 1 1 2
P. mirabilis 1 1 1 2 2 1 3
P. aeruginosa 1 2 1 2 6
FUSIDIC ACID
MRSA 5 4
MSSA 1 6 1
MRSE 3 1 2 1 1 2 2 1
E. faecalis 1 6 6
S. pyogenes 4 2
P. acnes 4 5 1
Drugs
Stock solutions of chlorquinaldol (MedChemtronica AB,
Stockholm, Sweden), fusidic acid (Cayman Chemical, Ann
Arbor, MI, USA), and gentamicin (MP Biomedicals, Santa Ana,
CA, USA) were prepared in 95% ethanol (chlorquinaldol) or
sterile water (fusidic acid and gentamicin) at concentrations
of 5,000 mg/L and stored in aliquots at −20◦C until
use.
Evaluation of Minimum Inhibitory
Concentration (MIC) and Minimum
Bactericidal Concentration (MBC)
The bacteriostatic and bactericidal properties of chlorquinaldol
and its spectrum of activity were evaluated in comparison with
gentamicin and fusidic acid.
The antimicrobial activity was assessed by determining the
MIC and the MBC-values against the microbial strains described
above. TheMIC was determined by broth microdilution method,
in accordance with EUCAST standard1. Briefly, a suspension in
growth medium (Brain heart infusion broth, Biomérieux, Marci
1http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/MIC_testing/
Edis5.1_broth_dilution.pdf
l’Etoile, France) was prepared for each bacterial strain with an
optical density equal to 0.5 McFarland (1.5 × 108 CFU/ml). For
P. acnes broth was supplemented with 3% of defibrinated sheep
blood (Liofilchem, Roseto degli Abruzzi, Italy). After obtaining
a concentration of 105 CFU/ml using appropriate dilutions,
each suspension was inoculated in a 96-wells microtiter plate
containing a serial 2-fold dilution of chlorquinaldol, fusidic
acid, or gentamicin. MIC-values, corresponding to the lowest
concentration exhibiting no visible bacterial growth, were read
after 24 h of incubation at proper conditions (except for
P. acnes that required 48 h). The MBC was determined by
plating 10 µl from each well showing no turbidity onto agar
plates. After incubation at proper conditions, MBC was read
as the lowest concentration able to kill 99.9% of the initial
inoculum.
Time-Kill Curves
Killing curves were performed against one representative strains
of each species described above. Briefly, a suspension in growth
medium was prepared for each bacterial strain with an optical
density equal to 0.5 McFarland (1.5 × 108 CFU/mL). An aliquot
was inoculated into test tubes containing 2ml of growth medium
alone (growth control) or containing each testing substance
(see above) at different concentrations (¼×, ½×. 1×, 2×, and
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TABLE 4 | MBC distributions (mg/L).
<0.016 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 >512
CHLORQUINALDOL
MRSA 2 2 1 3 1
MSSA 1 1 6
MRSE 2 1 3 1 2 3 1
E. faecalis 1 1 7 4
S. pyogenes 3 2 1
P. acnes 2 4 1 2 1
E. coli 12
P. aeruginosa 1 1 5 5
Enterobacter spp. 12
P. mirabilis 1 3 7
GENTAMICIN
MRSA 1 3 1 1 3
MSSA 1 4 1 1 1
MRSE 3 1 1 1 1 3 2 1
P. acnes 10
E. coli 4 3 1 1 1 2
P. aeruginosa 1 1 1 1 2 6
Enterobacter spp. 4 3 1 1 3
P. mirabilis 1 1 1 5 3
FUSIDIC ACID
MRSA 2 1 1 2 3
MSSA 2 1 1 1 3
MRSE 1 2 3 2 1 1 2 1
E. faecalis 1 5 7
S. pyogenes 3 1 2
P. acnes 2 6 1 1
4× MIC). Final concentration of bacteria was 5 × 105–5 × 106
CFU/mL. Tubes were incubated at 37◦C in proper conditions.
Microbial counts were performed after 0, 3, 6, 9, 24, and 48 h
of incubation by plating 0.1 mL of a proper dilution of bacterial
suspension onto agar plates. Results were expressed as Log10
(CFU/mL). The limit of count detection was 200 CFU/mL.
Bactericidal activity was defined as a 3 Log10 decrease in CFU/mL
(99.9% kill) of the initial inoculum. Bacteriostatic activity was
defined as <99.9% kill.
Time-kill curves of gentamicin and fusidic acid were
performed only on strains classified as susceptible according to
EUCAST breakpoint2.
RESULTS
Chlorquinaldol, Fusidic Acid, and
Gentamicin Antibacterial Activity
Tables 1, 2 show MIC and MBC ranges, while Tables 3, 4 show
distributions of MIC and MBC-values for chlorquinaldol, fusidic




Among Gram positives, staphylococci resulted the most sensitive
cocci to chlorquinaldol, which was able to inhibit bacterial
growth at concentrations ranging between 0.016 and 0.5 mg/L.
MBC-values were highly variable: in 47% of cases they were
equal or 2-fold the MIC, in 37% 4–8-folds the MIC, and in the
remaining 16% they were 16–32-folds the MIC. Chlorquinaldol
was effective at low concentrations against E. faecalis, presenting
MIC and MBC-values ranging from 0.25 to 2 mg/L. MBC-
values were always close to MIC-values (equal or 2-folds higher
than the MIC). Modest inhibitory activity was observed against
S. pyogenes and P. acnes.
All staphylococci with the exception of five MRSE strains
resulted resistant to gentamicin. All P. acnes presented MIC
and MBC-values higher than 512 mg/L. Staphylococci displayed
the highest variability among the tested strains with MIC and
MBC-values ranging from 0.25 to 1,024 mg/L.
All S. aureus strains were susceptible to fusidic acid, presenting
MIC-values varying from 0.016 to 0.032 mg/L, with the
exception of one MSSA isolate (MIC 2 mg/L). Eight strains of
S. epidermidis were susceptible to fusidic acid, while five strains
were found to be resistant. Propionibacteria were inhibited by
low concentrations of fusidic acid, while higher MIC-values were
observed for E. faecalis and S. pyogenes. Generally, MBC of
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fusidic acid were 4–128 times higher than the corresponding
MIC.
Gram-Negative Bacterial Strains
Gram-negative strains revealed a high heterogeneity in
distribution of gentamicin resistance, so that susceptible
and resistant strains are reported separately in Table 2. Strains
with a MIC-value higher than 4 mg/L were 50% of E. coli, 75% of
P. aeruginosa, 33% of Enterobacter spp., and 81% of P. mirabilis.
MBC-values were close to MIC-values (equal or two times higher
than the MIC), except for one P. aeruginosa strain (MIC 2 mg/L,
MBC 32 mg/L).
Chlorquinaldol spectrum of activity revealed a lower activity
against Gram-negative bacilli in respect to the Gram-positive
tested bacteria, with 77% of the isolates being inhibited at
concentrations ranging from 128 to 512 mg/L and 23% being
inhibited at concentrations ≤32 mg/L. Of the latter group, 9
E. coli isolates showed aMIC-value of 8 mg/L, while 1 P. mirabilis
and 2 P. aeruginosa isolates showed a MIC-value of 32 mg/L.
MBC-values were ≥512 mg/L for 77% of tested strains (Table 4).
Time-Kill Curves
Figures 1–6 show the pattern of growth and kill by antibiotics of
the various microbial species tested, at different concentrations of
each of the tested antibiotics.
Gram-Positive Bacterial Strains
Time-kill curves for Gram-positive strains are reported in
Figures 1–4. Chlorquinaldol showed bactericidal activity, as
defined by a 3 log10 reduction in viable count, after 48
h for S. epidermidis (4× MIC), MSSA (4× MIC), MRSA
(4× MIC), and E. faecalis (4× and 2× MIC), and after
24 h and 48 h for S. pyogenes (4× and 2× MIC). 2
log10 reductions were observed for MRSA (2× MIC), P.
acnes (4× MIC), and E. faecalis (1× MIC) after 48 h of
exposure. Gentamicin (4× and 2× MIC concentrations) was
bactericidal against S. epidermidis after 24 and 48 h. Fusidic
acid was essentially bacteriostatic against staphylococci and
P. acnes.
Gram-Negative Bacterial Strains
Time-kill curves for Gram-negative strains are reported in
Figures 5, 6. Chlorquinaldol displayed a bactericidal activity
against P. aeruginosa after 48 h exposure (4× MIC) and against
P. mirabilis after 24 h (4× MIC) and 48 h (2× and 4× MIC).
2 log10 reductions were observed for E. coli (4× MIC) and
E. cloacae (4× MIC) after 48 h of exposure, and for P. mirabilis
after 24 h (2×MIC). Gentamicin was bactericidal against E. coli
after 6 h (4×MIC) and 9 h (2×MIC), against E. cloacae after 6 h
(2× and 4× MIC) and 9 h (1× MIC), and against P. aeruginosa
after 6 h (4×MIC) and 9 h (2×MIC).
DISCUSSION
SSTIs are common in both community and hospital settings.
They present with a wide clinical spectrum, from superficial
self-limiting infections to deep and potentially life-threatening
FIGURE 1 | Time-kill curves for S. epidermidis. (A) chlorquinaldol; (B) fusidic
acid; (C) gentamicin. Filled square, control; open square, ¼ × MIC; filled circle,
½ × MIC; open circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
ones (Ray et al., 2013). Gram-positive organisms, such as
staphylococci and S. pyogenes, are the dominant organisms
isolated in the acute infectious process, whereas Gram-negative
organisms are more often seen in chronic or postoperative
wounds (Cardona and Wilson, 2015).
In the recent years, there has been an increased incidence
in SSTIs as a consequence of a number of factors, such
as aging of the general population, higher incidence of
immunocompromised patients and emergence of multidrug-
resistant pathogens.
Topical antibiotics are key components in the management
of SSTIs, but the emergence of pathogens with decreased
susceptibility to available therapies has become an
emerging clinical problem often associated with treatment
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FIGURE 2 | Time-kill curves for S. aureus. (A) chlorquinaldol, MSSA; (B) fusidic acid, MSSA; (C) chlorquinaldol, MRSA; (D) fusidic acid, MRSA. Filled square, control;
open square, ¼ × MIC; filled circle, ½ × MIC; open circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
FIGURE 3 | Time-kill curves for (A) S. pyogenes, chlorquinaldol; (B) E. faecalis,
chlorquinaldol. Filled square, control; open square, ¼ × MIC; filled circle, ½ ×
MIC; open circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
failure. In this background, alternative treatments for
patients infected with bacteria resistant to conventional
antimicrobials are urgently required. Some possibilities
FIGURE 4 | Time-kill curves for P. acnes. (A) chlorquinaldol; (B) fusidic acid.
Filled square, control; open square, ¼ × MIC; filled circle, ½ × MIC; open
circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
comprise combination therapy or revival of older antimicrobial
agents, for which resistance has not been developed
yet.
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FIGURE 5 | Time-kill curves for P. aeruginosa. (A) chlorquinaldol; (B)
gentamicin. Filled square, control; open square, ¼ × MIC; filled circle, ½ ×
MIC; open circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
One of these old drugs is chlorquinaldol, which is
generally administered as an ointment in association with
topical corticosteroids (usually 1% chlorquinaldol plus
0.1% diflucortolone valerate) for the treatment of SSTIs. Its
percutaneous absorption is very small, narrowing the risk of
systemic effects (Degen et al., 1979). Few past studies showed its
efficacy in vivo against various skin and soft tissue diseases of
infectious nature (Maeder et al., 1983; Hoppe, 1988; Corrihons
et al., 1991). Nevertheless, recent investigations re-evaluating its
antimicrobial activity are lacking and its mechanism of action is
not clear yet.
Chlorquinaldol is a bihalogenated derivative of 8-
hydroxyquinoline. Antimicrobial effects of 8-hydroxyquinoline
and its derivatives, encompassing antibacterial, antimalarial,
antiviral, antitubercular, and antiplaque activities have been
previously reported (Prachayasittikul et al., 2013). It is assumed
that they take advantage of their lipophilicity to penetrate
bacterial cell membranes, where their antimicrobial action
is probably related to chelating activities (Anjaneyulu et al.,
1982; Hongmanee et al., 2007; Darby and Nathan, 2010). Metal
ions play an important role in biological processes, and metal
homeostasis is required for maintenance of cellular functions.
Chelatedmetals become unavailable, inhibiting certain metabolic
processes (Fraser and Creanor, 1975; Rohde et al., 1977; Chobot
et al., 2011; Skrivanova et al., 2016). Until now, neither
breakpoint nor pharmacodynamics data for chlorquinaldol,
nor studies reporting MIC-values for a wide range of both
Gram-positive and Gram-negative microorganisms are available.
In this context, it is difficult to define a spectrum of activity for
chlorquinaldol.
In the present study, chlorquinaldol exerted growth-
inhibitory effects at different concentrations, depending on the
species in exam. In particular, it seemed to be more effective
against Gram-positive bacteria, especially staphylococci and
enterococci, which are the most frequent microorganisms
causing skin infections (Zlatkov et al., 1996; Lipsky et al., 2007).
Skrivanova et al. suggested that interspecies variability in the
response to 8-hydroxyquinolines might be due to the different
capacities of bacteria to accumulate metallic ions (Skrivanova
et al., 2016). Hence, the role of metalloenzymes in different
species should be explored to identify the mechanism of
chlorquinaldol antibacterial action.
In this study, the most prominent effects exerted by
chlorquinaldol were observed on staphylococci. In a past work,
Mann et al. evaluated the antimicrobial activity of chlorquinaldol
against 200 strains of S. aureus, reporting much higher MIC-
values (6–100 mg/L) than those observed in the present
manuscript (Mann et al., 1960). The reason for this discrepancy is
unknown; we hypothesize that it may be due to less standardized
methods respect to present international guidelines. In example,
no informations about the inoculum are provided, nor about the
manufacturer of chlorquinaldol, the exact formulation and the
purity.
In the present work, inhibitory concentrations of
chlorquinaldol were slightly higher than those of fusidic
acid, but differently from this latter, activity of chlorquinaldol
was mainly bactericidal. This activity was confirmed by the time-
kill curves: chlorquinaldol was bactericidal for both S. aureus and
S. epidermidis, killing more than 99.9% of the initial inoculum
at 48 h at 4× MIC concentrations, while fusidic acid displayed
a classical bacteriostatic trend. Furthermore, five MRSE and
one MSSA were resistant to fusidic acid while all MIC of the
staphylococci tested for chlorquinaldol fell into a narrower range
of action, always below a concentration of 0.5 mg/L. These data
are of particular interest because of the long time documented
emergence of fusidic acid resistance associated with topical
monotherapy, which is five times higher than in oral treatment
(Turnidge and Collignon, 1999; Howden and Grayson, 2006;
Heng et al., 2013; Williamson et al., 2014). Though gentamicin
showed a bactericidal effect at a concentration of 2× MIC at
24 h against the tested staphylococci, only 20% of tested strains
resulted susceptible to gentamicin. Indeed, high percentages
of gentamicin-resistance in staphylococci isolated from skin
infections have been reported by other authors, and nosocomial
outbreaks of gentamicin-resistant S. aureus associated with
the use of topical gentamicin were described in the past (Bint
et al., 1977; Wyatt et al., 1977; Graham et al., 1980; Moet et al.,
2007; Iwaki et al., 2011; Caraciolo et al., 2012). Moreover,
use of gentamicin impregnated collagen sponges has been
recently associated to an increased probability of sternal wound
infection after cardiac surgery caused by gentamicin-resistant
bacteria (Rapetto et al., 2016). As shown by time-kill curves,
chlorquinaldol was bactericidal also against E. faecalis and
S. pyogenes, at concentration of 2× MIC, while no bactericidal
effects were observed against P. acnes. All the tested E. faecalis
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FIGURE 6 | Time-kill curves for enterobacteriaceae. (A) E. coli, chlorquinaldol; (B) E. coli, gentamicin; (C) E. cloacae, chlorquinaldol; (D) E. cloacae, gentamicin; (E)
P. mirabilis, chlorquinaldol. Filled square, control; open square, ¼ × MIC; filled circle, ½ × MIC; open circle, 1 × MIC; filled triangle, 2 × MIC; open triangle, 4 × MIC.
strains were susceptible to chlorquinaldol at low concentrations,
with an MBC-value equal or 2-fold the MIC-value. Considering
the intrinsic resistance to gentamicin of this species and the
poor activity of fusidic acid on our isolates, which is in line with
literature review, chlorquinaldol can represent a valid choice to
treat E. faecalis infections (Collignon and Turnidge, 1999).
Chlorquinaldol was effective against all the Gram-negative
strains at high concentrations. We observed gentamicin
resistance in more than 60% of the tested strains, which is higher
than that observed in the SENTRY Antimicrobial Surveillance
Program over a 7-year period (1998–2004) in SSTI (Moet et al.,
2007).
Considering that, usually, topical formulations contain high
concentrations of antibiotics, it may be hypothesized that
chlorquinaldol levels at the infection site might be much higher
than the MIC observed in this study.
In conclusion, chlorquinaldol, due to its wide spectrum of
activity, would provide a valuable alternative for the treatment
of SSTIs. Moreover, its use in combination with other antibiotics
could be hypothesized in order to enhance antimicrobial activity
and to limit the increasing resistance to topical antibiotics.
Further, studies aiming to define a clinical breakpoint, evaluate
synergy with other compounds and the ability to select for
resistance after antibiotic exposure are advisable in the next
future. Old studies pointed out chlorquinaldol efficacy against
mycotic infections, so additional investigations to update its
spectrum of activity against fungi would be also of great interest.
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